Amplia Therapeutics (ASX:ATX) EBIT: A$-7.69 Mil (TTM As of Mar. 2026)

What is Amplia Therapeutics EBIT?

Amplia Therapeutics ASX:ATX +8.00% 36 EBIT is A$-7.69 Mil as of Mar. 2026. GuruFocus rates ASX:ATX with a GF Score™ of 36/100. The stock has 2 warning signs investors should review.

Amplia Therapeutics's earnings before interest and taxes (EBIT) for the six months ended in Mar. 2026 was A$-3.52 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was A$-7.69 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Amplia Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 was -93.64%. Amplia Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -216.63%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Amplia Therapeutics's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -18.40%.

Amplia Therapeutics (ASX:ATX) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Amplia Therapeutics's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

	ROC % (Q: Mar. 2026 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Sep. 2025 )	+	Invested Capital (Q: Mar. 2026 ))	/ count )
=	-12.346 * ( 1 - 0% )	/	( (14.268	+	12.1)	/ 2 )
=	-12.346	/	13.184
=	-93.64 %

where

	Invested Capital		(Q: Sep. 2025 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	44.54	-	1.116	-	( 29.156	-	max(0, 1.281	-	36.093	+	29.156	))
=	14.268

	Invested Capital		(Q: Mar. 2026 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	41.441	-	1.487	-	( 27.854	-	max(0, 1.67	-	33.042	+	27.854	))
=	12.1

Note: The Operating Income data used here is two times the semi-annual (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Amplia Therapeutics's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2026 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Sep. 2025		Q: Mar. 2026
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-7.036	/	( ( (0.402 + max(5.74, 0))	+	(0.354 + max(-1.171, 0)) )	/	2 )
=	-7.036	/	( ( 6.142	+	0.354 )	/	2 )
=	-7.036	/	3.248
=	-216.63 %

where Working Capital is:

	Working Capital		(Q: Sep. 2025 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	6.937)	-	(1.116	+	0	+	0.081)
=	5.74

	Working Capital		(Q: Mar. 2026 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	0.41)	-	(1.487	+	0	+	0.094)
=	-1.171

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Amplia Therapeutics's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2026 )
	=	-7.69	/	41.784
	=	-18.40 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Amplia Therapeutics EBIT Related Terms

Amplia Therapeutics EBIT Historical Data

* Premium members only.

The historical data trend for Amplia Therapeutics's EBIT can be seen below:

Amplia Therapeutics EBIT Chart

Amplia Therapeutics Annual Data

Trend

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Mar25

Mar26

EBIT

Get a 7-Day Free Trial

-3.64

-6.19

-4.43

-6.52

-7.69

Amplia Therapeutics Semi-Annual Data
	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24	Sep24	Mar25	Sep25	Mar26
EBIT	Get a 7-Day Free Trial															-3.34	-2.76	-3.76	-4.17	-3.52

ASX:ATX vs VRTX, REGN, ALNY: EBIT Comparison

For the Biotechnology subindustry, Amplia Therapeutics's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Amplia Therapeutics EV-to-EBIT vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Amplia Therapeutics's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Amplia Therapeutics's EV-to-EBIT falls into.

Save Embed

36GF Score

Amplia Therapeutics Ltd ASX:ATX

EBIT is just one metric. See GF Score™, valuation, warning signs, and more.

View Full Analysis

Amplia Therapeutics EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$-7.69 Mil.

Frequently Asked Questions Learn more about EBIT →

What does a EBIT of A$-7.69 Mil mean?

Amplia Therapeutics (ASX:ATX) has a EBIT of A$-7.69 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Amplia Therapeutics.

Is Amplia Therapeutics' EBIT too high?

Amplia Therapeutics' current EBIT is A$-7.69 Mil. Overall, Amplia Therapeutics has a GF Score™ of 36/100, reflecting its overall financial health beyond just this single metric.

How does Amplia Therapeutics' EBIT compare to VRTX and REGN?

Amplia Therapeutics' EBIT of A$-7.69 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good EBIT for a Biotechnology company?

A good EBIT depends on the Biotechnology industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high EBIT mean?

A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Amplia Therapeutics. Amplia Therapeutics's current EBIT is A$-7.69 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Amplia Therapeutics stock overvalued right now?

Amplia Therapeutics (ASX:ATX) has a current EBIT of A$-7.69 Mil. The current EBIT is A$-7.69 Mil. Amplia Therapeutics' overall GF Score™ is 36/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is EBIT calculated?

EBIT is calculated from a company's financial statements. For Amplia Therapeutics (ASX:ATX), the current EBIT is A$-7.69 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Amplia Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies ASX:CYP ASX:LTP ASX:BOT ASX:IMM ASX:PTX ASX:ENP ASX:ALA ASX:PAR ASX:NXN ASX:IMU VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY RVMD ASX:CSL ONC XKRX:068270

Other Exchanges INNMF:USA

Address 90 William Street, Level 5, Melbourne, VIC, AUS, 3000

Website https://www.ampliatx.com

Amplia Therapeutics Ltd is an Australian, clinical-stage, drug development company advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. The company is focused on the development of these drug candidates for potential use in multiple indications in oncology (e.g. pancreatic cancer) and chronic fibrotic diseases. Its molecule, AMP945 is a selective and potent inhibitor of FAK and is currently in a phase 2 clinical trial for pancreatic cancer, in clinical development for ovarian cancer, and preclinical development for idiopathic pulmonary fibrosis (IPF).

36GF Score

Get the complete analysis for ASX:ATX

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$0.14

Price

View ASX:ATX Analysis

See EBIT data for all stocks →